

## Special Issue

# Safety and Immunogenicity of Vaccination

### Message from the Guest Editor

Vaccination remains one of the most transformative public health interventions. This Special Issue aims to collate cutting-edge research, clinical trial outcomes, and mechanistic insights into vaccine-induced immune responses. The issue will serve to guide those working to ensure the safety and effectiveness of vaccines, especially in the context of vaccine preparedness. We welcome original articles, systematic reviews, and short communications that address:

- Preclinical and clinical safety profiles of emerging vaccine candidates;
- Kinetics and quality of immune responses (e.g., durability, breadth, avidity);
- Correlates of protection across different vaccine platforms;
- Comparative immunogenicity across age groups, immunocompromised individuals, and special populations;
- Biomarkers for vaccine efficacy and adverse events;
- Innovations in vaccine formulation, delivery, and adjuvant systems.

This issue will serve as a reference point for scientists, regulators, and policymakers working to ensure the **safety and effectiveness of next-generation vaccines**, particularly in the context of pandemic preparedness and global equity.

### Guest Editor

Dr. Jennifer Serwanga

1. Department of Immunology, Uganda Virus Research Institute, Entebbe P.O. Box 49, Uganda
2. Medical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda
3. London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

### Deadline for manuscript submissions

31 May 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/244077](https://mdpi.com/si/244077)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).